Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 7, 2023; 29(25): 3999-4008
Published online Jul 7, 2023. doi: 10.3748/wjg.v29.i25.3999
Insulin resistance and adipose tissue interactions as the cornerstone of metabolic (dysfunction)-associated fatty liver disease pathogenesis
Shreya C Pal, Nahum Méndez-Sánchez
Shreya C Pal, Nahum Méndez-Sánchez, Faculty of Medicine, National Autonomous University of Mexico, Mexico City 04510, Mexico
Shreya C Pal, Nahum Méndez-Sánchez, Liver Research Unit, Medica Sur Clinic & Foundation, Mexico City 04510, Mexico
Author contributions: Pal SC contributed to manuscript writing, data analysis, and critical revision; Méndez-Sánchez N contributed to conceptualization, manuscript design, critical revision, and supervision.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Nahum Méndez-Sánchez, FAASLD, AGAF, FACG, MD, MSc, PhD, Researcher, Liver Research Unit, Medica Sur Clinic & Foundation, Puente de Piedra 150, Col. Toriello Guerra, Mexico City 04510, Mexico.
Received: December 6, 2022
Peer-review started: December 6, 2022
First decision: January 22, 2023
Revised: February 9, 2023
Accepted: March 20, 2023
Article in press: March 20, 2023
Published online: July 7, 2023
Core Tip

Core Tip: In this review, we outline the main arguments that support the importance of insulin resistance (IR) in fatty liver pathogenesis, stressing its role in metabolic dysfunction. IR and other genetic and molecular mechanisms play a pivotal role not only in metabolic dysfunction–associated fatty liver disease development but also in some of its complications and comorbidities, such as chronic kidney disease.